# Dejan Juric

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8609575/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 141 papers | 8,750 citations | 126907 33 h-index | 48315 88 g-index |
| 145 all docs | 145 docs citations | 145 times ranked | 12922 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Deep learning enables genetic analysis of the human thoracic aorta. Nature Genetics, 2022, 54, 40-51. | 21.4 | 90 |
| 2 | Vascular smooth muscle cell phenotype switching in carotid atherosclerosis. JVS Vascular Science, 2022, 3, 41-47. | 1.1 | 6 |
| 3 | First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety. Journal of Clinical Oncology, 2022, 40, 360490-360490. | 1.6 | 34 |
| 4 | Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer. Cancer Research, 2022, 82, P3-09-11-P3-09-11. | 0.9 | 0 |
| 5 | Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. Cancer Research, 2022, 82, P1-18-03-P1-18-03. | 0.9 | 3 |
| 6 | Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). Cancer Research, 2022, 82, P2-07-02-P2-07-02. | 0.9 | 1 |
| 7 | Abstract P1-17-03: H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study. Cancer Research, 2022, 82, P1-17-03-P1-17-03. | 0.9 | 2 |
| 8 | Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer. Cancer Research, 2022, 82, P5-17-05-P5-17-05. | 0.9 | 3 |
| 9 | Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies. Cancer Research, 2022, 82, P5-13-18-P5-13-18. | 0.9 | 0 |
| 10 | Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. Cancer Research, 2022, 82, P1-18-22-P1-18-22. | 0.9 | 0 |
| 11 | Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (â‰¤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve. Cancer Research, 2022, 82, P1-18-08-P1-18-08. | 0.9 | 4 |
| 12 | Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial. Cancer Research, 2022, 82, PD15-01-PD15-01. | 0.9 | 3 |
| 13 | Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study. Cancer Research, 2022, 82, P1-17-10-P1-17-10. | 0.9 | 5 |
| 14 | Abstract P1-18-07: Impact of PIK3CA mutation (PIK3CA-mt) clonality on alpelisib (ALP) activity based on real-world evidence (RWE) following liquid biopsy testing. Cancer Research, 2022, 82, P1-18-07-P1-18-07. | 0.9 | 0 |
| 15 | Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study. Cancer Research, 2022, 82, P5-13-03-P5-13-03. | 0.9 | 4 |
| 16 | EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusionâ€“Positive Cholangiocarcinoma. Cancer Discovery, 2022, 12, 1378-1395. | 9.4 | 33 |
| 17 | Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence.. Journal of Clinical Oncology, 2022, 40, e13592-e13592. | 1.6 | 0 |
| 18 | Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).. Journal of Clinical Oncology, 2022, 40, 1052-1052. | 1.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Relationship of travel distance with patient demographics, advance care planning, and survival in early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2022, 40, 6558-6558. | 1.6 | 0 |
| 20 | Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptorâ€“positive (HR+), human epidermal growth factor receptor 2â€“negative (HER2â˜) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. Journal of Clinical Oncology, 2022, 40, 1006-1006. | 1.6 | 4 |
| 21 | Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation. Cancer Research, 2022, 82, 5162-5162. | 0.9 | 1 |
| 22 | Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. JCO Precision Oncology, 2022, , . | 3.0 | 1 |
| 23 | Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.. Journal of Clinical Oncology, 2022, 40, 1018-1018. | 1.6 | 3 |
| 24 | Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology, 2022, 40, 3084-3084. | 1.6 | 0 |
| 25 | Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation. Cancer Research, 2022, 82, 2638-2638. | 0.9 | 14 |
| 26 | Abstract 1789: Chromatin modifier alterations confer resistance to endocrine deprivation and CDK4/6 inhibitors in ER+ breast cancer and drive convergent evolution in patient autopsy lesions. Cancer Research, 2022, 82, 1789-1789. | 0.9 | 2 |
| 27 | Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.. Journal of Clinical Oncology, 2022, 40, 2507-2507. | 1.6 | 1 |
| 28 | Protocol requirements and logistical intensity of early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2022, 40, e18609-e18609. | 1.6 | 0 |
| 29 | Patient-reported hope, quality of life (QOL), symptom burden, and coping mechanisms in early phase clinical trial participants.. Journal of Clinical Oncology, 2022, 40, 12114-12114. | 1.6 | 0 |
| 30 | Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, TPS4180-TPS4180. | 1.6 | 1 |
| 31 | Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients withPIK3CA-Mutant Cancers. Clinical Cancer Research, 2021, 27, 447-459. | 7.0 | 22 |
| 32 | Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3404-3413. | 7.0 | 10 |
| 33 | Abstract PS18-19: Comparison of metastatic genomic profile in patients â‰¤45 years and patients >45 years with triple-negative breast cancer. , 2021, , . | | 0 |
| 34 | Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer. , 2021, , . | | 0 |
| 35 | Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncology, The, 2021, 22, 489-498. | 10.7 | 157 |
| 36 | COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature, 2021, 595, 107-113. | 27.8 | 537 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RASâ€“MAPK Reactivation. Cancer Discovery, 2021, 11, 1913-1922. | 9.4 | 243 |
| 38 | Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptorâ€“positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.. Journal of Clinical Oncology, 2021, 39, e13025-e13025. | 1.6 | 5 |
| 39 | Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nature Communications, 2021, 12, 3199. | 12.8 | 33 |
| 40 | Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.. Journal of Clinical Oncology, 2021, 39, TPS2667-TPS2667. | 1.6 | 0 |
| 41 | Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.. Journal of Clinical Oncology, 2021, 39, 1018-1018. | 1.6 | 22 |
| 42 | Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).. Journal of Clinical Oncology, 2021, 39, 1054-1054. | 1.6 | 4 |
| 43 | Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFÎ² inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.. Journal of Clinical Oncology, 2021, 39, 2510-2510. | 1.6 | 2 |
| 44 | Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer From SOLAR-1. Journal of Clinical Oncology, 2021, 39, 2005-2015. | 1.6 | 23 |
| 45 | Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discovery, 2021, 11, 2436-2445. | 9.4 | 69 |
| 46 | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 103. | 5.2 | 17 |
| 47 | A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5760-5770. | 7.0 | 25 |
| 48 | Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. Journal of Hematology and Oncology, 2021, 14, 127. | 17.0 | 12 |
| 49 | Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886. | | 9 |
| 50 | Identifying early-phase clinical trial (EP-CT) participants at risk for poor outcomes.. Journal of Clinical Oncology, 2021, 39, 301-301. | 1.6 | 0 |
| 51 | Time burden and logistical intensity of early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2021, 39, 84-84. | 1.6 | 0 |
| 52 | Supportive care services and goals of care in early phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2021, 39, 26-26. | 1.6 | 2 |
| 53 | Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-8. | 4.9 | 36 |
| 54 | Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nature Communications, 2021, 12, 5954. | 12.8 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | 369â€…Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers. , 2021, 9, A397-A397. | | 2 |
| 56 | Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors. Frontiers in Oncology, 2021, 11, 786120. | 2.8 | 5 |
| 57 | CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-Oncology, 2021, 23, vi49-vi49. | 1.2 | 0 |
| 58 | PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3KÎ± Inhibitors in Breast Cancer. Cancer Discovery, 2020, 10, 72-85. | 9.4 | 154 |
| 59 | Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers. Cancer Discovery, 2020, 10, 86-103. | 9.4 | 100 |
| 60 | Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262. | 3.0 | 16 |
| 61 | Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21. | 5.4 | 36 |
| 62 | Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nature Communications, 2020, 11, 6319. | 12.8 | 203 |
| 63 | Overall Survival of CDK4/6-Inhibitorâ€“Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1089-1097. | 6.3 | 59 |
| 64 | Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 4852-4862. | 7.0 | 12 |
| 65 | Cell Atlas of The Human Fovea and Peripheral Retina. Scientific Reports, 2020, 10, 9802. | 3.3 | 145 |
| 66 | A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Investigational New Drugs, 2020, 38, 1483-1494. | 2.6 | 15 |
| 67 | 401â€…Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , . | | 2 |
| 68 | Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. Journal of Clinical Oncology, 2020, 38, 1006-1006. | 1.6 | 52 |
| 69 | Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. Journal of Clinical Oncology, 2020, 38, 1066-1066. | 1.6 | 13 |
| 70 | Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. Journal of Clinical Oncology, 2020, 38, 1094-1094. | 1.6 | 1 |
| 71 | Involvement of social work services in patients with advanced cancer in early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2020, 38, 28-28. | 1.6 | 0 |
| 72 | Understanding the supportive care needs of early-phase cancer clinical trial (CT) participants.. Journal of Clinical Oncology, 2020, 38, 26-26. | 1.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Palliative care referrals in patients with advanced cancer on early-phase cancer clinical trials (EP-CTs).. Journal of Clinical Oncology, 2020, 38, 29-29. | 1.6 | 6 |
| 74 | Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Investigational New Drugs, 2019, 37, 271-281. | 2.6 | 7 |
| 75 | Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18. | 5.4 | 25 |
| 76 | Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421. | 30.7 | 359 |
| 77 | Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell Chemical Biology, 2019, 26, 1067-1080.e8. | 5.2 | 151 |
| 78 | TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€“Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079. | 9.4 | 254 |
| 79 | Alpelisib for PIK3CA-Mutated, Hormone Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2019, 380, 1929-1940. | 27.0 | 1,582 |
| 80 | Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 175, 649-658. | 2.5 | 5 |
| 81 | A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. Breast Cancer Research and Treatment, 2019, 174, 605-613. | 2.5 | 14 |
| 82 | Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptorâ€“Positive Advanced Breast Cancer. JAMA Oncology, 2019, 5, e184475. | 7.1 | 187 |
| 83 | Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2019, 37, 1028-1028. | 1.6 | 5 |
| 84 | Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.. Journal of Clinical Oncology, 2019, 37, 1038-1038. | 1.6 | 1 |
| 85 | Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2â€“negative (HER2â€“) advanced breast cancer (ABC) from SOLAR-1.. Journal of Clinical Oncology, 2019, 37, 1039-1039. | 1.6 | 2 |
| 86 | Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.. Journal of Clinical Oncology, 2019, 37, 1040-1040. | 1.6 | 15 |
| 87 | A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1057-1057. | 1.6 | 27 |
| 88 | Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERÎ± Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).. Journal of Clinical Oncology, 2019, 37, 1059-1059. | 1.6 | 9 |
| 89 | NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.. Journal of Clinical Oncology, 2019, 37, 3043-3043. | 1.6 | 2 |
| 90 | A phase I open label study evaluating VT1021 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS3158-TPS3158. | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.. Journal of Clinical Oncology, 2019, 37, 1052-1052. | 1.6 | 0 |
| 92 | Firstâ€inâ€human trial of the PI3KÎ²â€selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer, 2018, 124, 315-324. | 4.1 | 29 |
| 93 | Phosphatidylinositol 3-Kinase Î±â€“Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology, 2018, 36, 1291-1299. | 1.6 | 298 |
| 94 | Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens. Nature Communications, 2018, 9, 4550. | 12.8 | 47 |
| 95 | Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2018, 36, 1004-1004. | 1.6 | 14 |
| 96 | A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).. Journal of Clinical Oncology, 2018, 36, 2547-2547. | 1.6 | 6 |
| 97 | Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, e15124-e15124. | 1.6 | 3 |
| 98 | BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.. Journal of Clinical Oncology, 2018, 36, TPS1107-TPS1107. | 1.6 | 8 |
| 99 | Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS2600-TPS2600. | 1.6 | 2 |
| 100 | Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. Journal of Clinical Oncology, 2018, 36, 1021-1021. | 1.6 | 0 |
| 101 | Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 1020-1020. | 1.6 | 10 |
| 102 | A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34. | 7.0 | 268 |
| 103 | A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2017, 23, 5015-5023. | 7.0 | 65 |
| 104 | Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery, 2017, 7, 704-715. | 9.4 | 127 |
| 105 | Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusionâ€“Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263. | 9.4 | 384 |
| 106 | High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. JCO Precision Oncology, 2017, 1, 1-9. | 3.0 | 6 |
| 107 | A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646. | 2.6 | 24 |
| 108 | Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2141-2148. | 1.6 | 283 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. Journal of Clinical Oncology, 2017, 35, 1013-1013. | 1.6 | 5 |
| 110 | Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, 1046-1046. | 1.6 | 4 |
| 111 | Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. Journal of Clinical Oncology, 2017, 35, TPS1106-TPS1106. | 1.6 | 1 |
| 112 | A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.. Journal of Clinical Oncology, 2017, 35, TPS1111-TPS1111. | 1.6 | 6 |
| 113 | A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3104-TPS3104. | 1.6 | 1 |
| 114 | Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419. | 5.0 | 28 |
| 115 | CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381. | 6.4 | 215 |
| 116 | Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2â€“) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.. Journal of Clinical Oncology, 2016, 34, 568-568. | 1.6 | 25 |
| 117 | SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2â€“ advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.. Journal of Clinical Oncology, 2016, 34, TPS618-TPS618. | 1.6 | 13 |
| 118 | Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509. | 1.6 | 3 |
| 119 | Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.. Journal of Clinical Oncology, 2016, 34, TPS11621-TPS11621. | 1.6 | 0 |
| 120 | Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509. | 1.6 | 0 |
| 121 | Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. Blood, 2016, 128, 2749-2749. | 1.4 | 0 |
| 122 | Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clinical Cancer Research, 2015, 21, 2462-2470. | 7.0 | 51 |
| 123 | AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546. | 16.8 | 263 |
| 124 | Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244. | 27.8 | 486 |
| 125 | First-in-human, phase I, dose-escalation study of selective PI3KÎ± isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.. Journal of Clinical Oncology, 2015, 33, 2501-2501. | 1.6 | 5 |
| 126 | First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. Journal of Clinical Oncology, 2015, 33, 2564-2564. | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Science Signaling, 2014, 7, ra29. | 3.6 | 123 |
| 128 | Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates. Science Translational Medicine, 2014, 6, 219ra9. | 12.4 | 142 |
| 129 | CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors. Cancer Cell, 2014, 26, 136-149. | 16.8 | 375 |
| 130 | A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. Journal of Clinical Oncology, 2014, 32, 2517-2517. | 1.6 | 10 |
| 131 | A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.. Journal of Clinical Oncology, 2014, 32, 2519-2519. | 1.6 | 9 |
| 132 | SU2C phase Ib study of the PI3KÎ± inhibitor BYL719 with letrozole in ER+/HER2â€“ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2014, 32, 516-516. | 1.6 | 2 |
| 133 | Phase Ib study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2â^' BC).. Journal of Clinical Oncology, 2014, 32, 533-533. | 1.6 | 13 |
| 134 | A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 9051-9051. | 1.6 | 52 |
| 135 | Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.. Journal of Clinical Oncology, 2014, 32, 143-143. | 1.6 | 19 |
| 136 | mTORC1 Inhibition Is Required for Sensitivity to PI3K p110Î± Inhibitors in PIK3CA -Mutant Breast Cancer. Science Translational Medicine, 2013, 5, 196ra99. | 12.4 | 251 |
| 137 | Safety, pharmacokinetics, and preliminary activity of the Î±-specific PI3K inhibitor BYL719: Results from the first-in-human study.. Journal of Clinical Oncology, 2013, 31, 2531-2531. | 1.6 | 34 |
| 138 | Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 533-533. | 1.6 | 0 |
| 139 | Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 145-145. | 1.6 | 0 |
| 140 | A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. Journal of Clinical Oncology, 2012, 30, 2568-2568. | 1.6 | 9 |
| 141 | Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567. | 1.6 | 1 |